Dr. Nanus Discusses Adjuvant Therapy for RCC

Video

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma (RCC).

Investigators are asking if there is anything to do for patients with RCC who have a high risk of relapse after surgery other than observation. Nanus says that for a long time, there was no improvement in overall survival in trials of adjuvant therapy. But, recently, a study of sunitinib (Sutent) in patients with high-risk RCC showed an improvement in progression-free survival.

Although there has been no improvement in overall survival yet, the NCCN guidelines changed to offer sunitinib adjuvant therapy as an option for these patients. The FDA then approved the agent for use as an adjuvant therapy in patients with RCC who have received nephrectomy and are at high risk for recurrence. This was based on the phase III S-TRAC trial, in which adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy.

Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Related Content
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Evaluating Autologous Cord Blood Derived Cells for the Treatment of Preterm Infants

April 8th 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed his lab’s research in the field of neonatal cell therapy.

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Standardized Guidelines for Preclinical Testing and Cell Characterization are Critical to Cell Therapy Development

April 3rd 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed the importance of preclinical guidelines in the context of neonatal cell therapy.

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

March 4th 2022
Article

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

June 27th 2021
Article

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

June 9th 2021
Article

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

© 2024 MJH Life Sciences

All rights reserved.